p38 (MAPK14) pTyr182 Rabbit Polyclonal Antibody
CAT#: AP02505PU-S
p38 (MAPK14) pTyr182 rabbit polyclonal antibody, Aff - Purified
Size: 100 ul
Need it in bulk or conjugated?
Get a free quote
CNY 1,400.00
货期*
2周
规格
Specifications
Product Data | |
Applications | IHC, WB |
Recommend Dilution | Western Blot: 1/500~1/1000. Immunohistochemistry: 1/50~1/100. |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Immunogen | The antiserum was produced against synthesized phosphopeptide derived from Human p38 MAPK around the phosphorylation site of tyrosine 182 (T-G-YP-V-A). |
Specificity | This antibody detects endogenous levels of P38MAPK only when phosphorylated at Tyrosine 182. |
Formulation | PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% Sodium Azide and 50% Glycerol. State: Aff - Purified State: Liquid purified Ig fraction. |
Concentration | lot specific |
Purification | Immunoaffinity Chromatography using epitope-specific phosphopeptide. |
Conjugation | Unconjugated |
Storage Condition | Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing. |
Gene Name | mitogen-activated protein kinase 14 |
Database Link | |
Synonyms | Mitogen-activated protein kinase 14, p38 alpha, MXI2, SAPK2A, CSBP, CSBP1, CSBP2, CSPB1 |
Note | For western blotting, incubate membrane with diluted antibody in 5% nonfat milk, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight. |
Reference Data | |
Protein Families | Druggable Genome, Protein Kinase |
Protein Pathways | Amyotrophic lateral sclerosis (ALS), Epithelial cell signaling in Helicobacter pylori infection, Fc epsilon RI signaling pathway, GnRH signaling pathway, Leukocyte transendothelial migration, MAPK signaling pathway, Neurotrophin signaling pathway, NOD-like receptor signaling pathway, Progesterone-mediated oocyte maturation, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...